Drug Trial Radar · NCT04351763
Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms
Last checked: Nov 20, 2026Latest source record: Sep 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
804
Actual
Start
May 20, 2020
Primary completion
May 25, 2021
Study completion Jun 5, 2021
Sponsor
- Lead sponsor
- Nicolaus Copernicus UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is an urgent need for effective therapies against the novel COVID-19 virus. Studies have shown that amiodarone and verapamil can interfere with coronavirus entry and amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with confirmed COVID-19 infection.
Conditions
- COVID-19
Interventions
AmiodaroneDrug
Ion channel blocker
VerapamilDrug
Ion channel blocker
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical improvementTime frame: Randomization to day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nicolaus Copernicus University
Bydgoszcz, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.